替雷利珠单抗联合舒尼替尼治疗转移性肾癌的临床疗效及生存分析

Clinical Efficacy and Survival Analysis of Tislelizumab Combined with Sunitinib in the Treatment of Metastatic Renal Cancer

【目的】探讨替雷利珠单抗联合舒尼替尼治疗转移性肾癌的临床疗效及生存结局。【方法】将42例转移性肾癌患者随机分为观察组和对照组,每组21例。观察组口服舒尼替尼联合静脉滴注替雷利珠单抗治疗,对照组口服舒尼替尼联合静脉滴注生理盐水治疗。治疗6个周期后,比较两组患者的疗效、不良反应发生情况及生存预后;比较两组患者治疗前后的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、基质金属蛋白酶2(MMP-2)、血管内皮生长因子(VEGF)、组织金属蛋白酶抑制剂-1(TIMP-1)水平。【结果】观察组疾病控制率为90.48%,高于对照组的61.90%,且差异有统计学意义(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)较治疗前均升高,且观察组高于对照组(P<0.05)。治疗后,两组MMP-2、VEGF及TIMP-1较治疗前均降低,且观察组低于对照组(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。对照组和观察组患者的中位无进展生存期(PFS)分别为11个月、15个月,两组中位PFS曲线比较,差异有统计学意义(P<0.05)。【结论】替雷利珠单抗联合舒尼替尼治疗转移性肾癌的疗效确切且安全性良好。

【Objective】To investigate the clinical efficacy and survival outcomes of tislelizumab combined with sunitinib in the treatment of metastatic renal cancer.【Methods】Forty-two patients with metastatic renal cancer were randomly divided into the observation group and the control group,with 21 patients in each group.The observation group was treated with oral sunitinib combined with intravenous tislelizumab,while the control group was treated with oral sunitinib combined with intravenous saline.After six treatment cycles,the efficacy,incidence of adverse reactions,and survival prognosis were compared between the two groups.Additionally,CD3^(+),CD4^(+),CD4^(+)/CD8^(+),matrix metalloproteinase-2(MMP-2),vascular endothelial growth factor(VEGF),and tissue inhibitor of metalloproteinases-1(TIMP-1)levels were measured before and after treatment and compared between the two groups.【Results】The disease control rate in the observation group was 90.48%,which was significantly higher than that of 61.90%in the control group(P<0.05).After treatment,CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)levels increased in both groups,with the observation group showing higher levels than the control group(P<0.05).MMP-2,VEGF,and TIMP-1 levels decreased in both groups post-treatment,with lower levels in the observation group compared to the control group(P<0.05).The incidence of adverse reactions between the two groups showed no statistically significant difference(P>0.05).The median progression-free survival(PFS)was 11 months in the control group and 15 months in the observation group,with a statistically significant difference between the PFS curves of the two groups(P<0.05).【Conclusion】Tislelizumab combined with sunitinib is effective and safe in the treatment of metastatic renal cancer.